Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares
(NQ:
LSE
)
4.450
-0.250 (-5.32%)
Delayed Quote
Updated: 11:51 AM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Seeing Machines launches Technical Paper demonstrating real-time 3D human understanding for Physical AI
September 30, 2026
Delivering up to 180 FPS on NVIDIA Jetson Thor, Seeing Machines HMR combines state-of-the-art accuracy with low latency and compact model size for embedded deployment
From
Seeing Machines
Via
GlobeNewswire
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
September 30, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
September 28, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
September 25, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
September 23, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
The Elmet Group Secures Long-Term Tungsten Offtake Agreement with Tungsten West’s Hemerdon Mine
September 22, 2026
From
The Elmet Group
Via
GlobeNewswire
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
September 16, 2026
From
Avacta Group PLC
Via
GlobeNewswire
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
September 14, 2026
From
Avacta Group PLC
Via
GlobeNewswire
PPHC Increases 2026 Interim Dividend to $0.117 Per Share
September 11, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 03, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
August 27, 2026
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
August 16, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Public Policy Holding Company, Inc. Announces Q2 2026 Financial Results
August 10, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
TierPoint Launches Adapt DDoS Protection
August 04, 2026
Always-On, Low-Latency DDoS Protection Powered by Corero Technology
From
TierPoint
Via
GlobeNewswire
PPHC Acquires Florida Government Relations Firm
August 03, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
HUTCHMED Reports 2026 Interim Results
July 30, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
PPHC to Report Second Quarter 2026 Financial Results and Present at Upcoming Investor Conference
July 27, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
PPHC Strengthens Public Affairs Offering with Hire of Managing Director and Content Specialist
July 14, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
July 08, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
July 02, 2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
From
HUTCHMED (China) Limited
Via
GlobeNewswire
PPHC Announces Acquisition of Tancredi
July 01, 2026
PPHC, TrailRunner International expands international footprint for financial, corporate and litigation communications in EMEA
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
June 26, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
June 24, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
June 23, 2026
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Leishen Energy Named as the No. 1 Bid Winner for Surface Control Integrated Devices with a Sinopec Oilfield
June 16, 2026
From
Leishen Energy Holding Co., Ltd.
Via
GlobeNewswire
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
June 11, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
June 01, 2026
From
Avacta Group PLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
